Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

Overview

Cellular therapies, particularly CAR-T cell treatments targeting BCMA and GPRC5D, have significantly improved outcomes in multiple myeloma (MM), especially in relapsed and refractory cases. Emerging strategies such as HLA-mismatched peripheral blood stem cell microtransplant and targeted immune therapies like daratumumab are expanding therapeutic options and reshaping management paradigms.

Background

Multiple myeloma treatment has been revolutionized by cellular therapies that reduce reliance on toxic chemotherapy. CAR-T cell therapy, especially targeting BCMA, has shown unprecedented responses in relapsed and refractory MM but is limited by relapse due to antigen escape and T-cell exhaustion. New targets like GPRC5D and alternative cellular approaches are under investigation to overcome these challenges. Additionally, immune therapies such as daratumumab are changing management strategies in smoldering myeloma, a precursor state to overt disease.

Data Highlights

Key Findings

• CAR-T therapies targeting BCMA have FDA approval for relapsed/refractory MM but are not curative, with relapse due to antigen escape and T-cell exhaustion.
• GPRC5D-directed CAR-T cells show higher overall and complete response rates and lower relapse rates compared to BCMA CAR-T, with a favorable toxicity profile.
• HLA-mismatched peripheral blood stem cell microtransplant demonstrates promising response rates and survival outcomes with lower toxicity in MM, warranting further prospective studies.
• Daratumumab, a CD38 monoclonal antibody, is now approved for high-risk smoldering myeloma, offering a survival benefit and delaying progression to overt disease.
• Advancements in CAR-T engineering (multi-antigen, armored, gated CARs) and off-the-shelf allogeneic CAR-T/NK cells are under investigation to improve efficacy and accessibility.
• Optimizing post-CAR-T interventions and scalable production strategies are critical to sustain treatment efficacy and expand patient access.

Clinical Implications

Clinicians should consider CAR-T therapies targeting BCMA and emerging targets like GPRC5D for relapsed/refractory MM, recognizing the potential for relapse and the need for post-treatment strategies. The promising outcomes with HLA-mismatched microtransplant suggest a lower-toxicity alternative that may be accessible to more patients. For high-risk smoldering myeloma, daratumumab offers a new therapeutic option that can delay progression, necessitating careful patient selection and monitoring.

Conclusion

Cellular therapies have transformed multiple myeloma management, with ongoing innovations aimed at overcoming resistance and improving accessibility. Continued research into novel targets, alternative cellular approaches, and integration of immune therapies will further refine treatment paradigms and patient outcomes.

References

1. Yu et al. -- Comprehensive overview of CAR-T in multiple myeloma
2. Yang et al. -- Meta-analysis of BCMA and GPRC5D CAR-T therapies in RRMM
3. Lei et al. -- Retrospective analysis of HLA-mismatched peripheral blood stem cell microtransplant in MM
4. Garg and Devarakonda -- Review of daratumumab in smoldering myeloma